Regeneron Pharmaceuticals Inc
Ownership
Ownership Structure
Who owns Regeneron Pharmaceuticals Inc (REGN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 94.7% of the shares are freely tradable; institutional investors hold 92.3%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 8.69 | 8,947,735 | +2.4 | 03/31/2026 |
| Vanguard Capital Management, LLC | 6.46 | 6,654,913 | +0.0 | 03/31/2026 |
| Dodge & Cox | 4.73 | 4,871,137 | +9.3 | 06/30/2026 |
| State Street Corp | 4.53 | 4,664,478 | +0.1 | 03/31/2026 |
| JPMorgan Chase & Co | 4.19 | 4,311,806 | +9.4 | 03/31/2026 |
| Amvescap Plc. | 3.79 | 3,905,109 | -0.2 | 03/31/2026 |
| Franklin Templeton Inc | 2.64 | 2,722,071 | +6.3 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.19 | 3,280,844 | +0.3 | 07/31/2026 |
| Dodge & Cox Stock I | 3.03 | 3,122,173 | +7.3 | 06/30/2026 |
| Vanguard 500 Index Investor | 2.55 | 2,622,268 | +1.1 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Larosa Joseph J | EVP General Counsel and Secret | 36,373 | 28,549,168 $ | Aug 19, 2026 | direct |
| Fenimore Christopher R. | EVP Finance CFO | 19,984 | 15,685,442 $ | Aug 18, 2026 | direct |
| McCourt Marion | EVP Commercial | 12,003 | 9,421,155 $ | Sep 3, 2026 | direct |
| Zoghbi Huda Y | Director | 1,703 | 1,336,685 $ | Aug 10, 2026 | direct |
| Guarini Kathryn | Director | 603 | 473,295 $ | Sep 2, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | McCourt Marion | EVP Commercial | Sell | 1,131 | 857.39 | 969,708 |
| Sep 2, 2026 | Guarini Kathryn | Director | Sell | 400 | 850.00 | 340,000 |
| Sep 2, 2026 | Guarini Kathryn | Director | Other | 400 | 719.37 | 287,748 |
| Sep 2, 2026 | McCourt Marion | EVP Commercial | Sell | 1,215 | 850.00 | 1,032,750 |
| Aug 19, 2026 | Larosa Joseph J | EVP General Counsel and Secret | Other | 9,019 | 830.15 | 7,487,123 |
| Aug 19, 2026 | Larosa Joseph J | EVP General Counsel and Secret | Other | 12,282 | 381.92 | 4,690,741 |
| Aug 18, 2026 | Fenimore Christopher R. | EVP Finance CFO | Other | 4,599 | 813.47 | 3,741,149 |
| Aug 18, 2026 | Fenimore Christopher R. | EVP Finance CFO | Other | 6,283 | 381.92 | 2,399,603 |
| Aug 10, 2026 | Guarini Kathryn | Director | Sell | 400 | 800.00 | 320,000 |
| Aug 10, 2026 | Guarini Kathryn | Director | Other | 400 | 719.37 | 287,748 |
| Aug 10, 2026 | Zoghbi Huda Y | Director | Sell | 800 | 800.00 | 640,000 |
| Aug 10, 2026 | Zoghbi Huda Y | Director | Other | 800 | 376.69 | 301,352 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.